Desmoid fibromatosis is a rare but locally aggressive tumor comprised of myofibroblasts.
the b-catenin or the APC genes are usually the cause for the development of these tumors with the former comprising the sporadic development of tumors and the latter being associated with familial adenomatous polyposis syndrome. Surgical resection with histologically negative margins has been the cornerstone of therapy for this disease, but this paradigm has begun to shift. It is now common to accept a microscopically positive margin after resection as recurrence rates may not be significantly affected. An even more radical evolution in management has been the recent movement towards ''watchful waiting'' when new desmoids are diagnosed. As the natural history of desmoids has become better understood, it is evident that some tumors will not grow and may even spontaneously regress sparing patients the morbidity of more aggressive therapy. Other modalities of treatment for desmoids include radiation and systemic therapy which both can be used adjuvantly or as definitive therapy and have shown durable response rates as single therapy regimens. The decision to use radiation and/or systemic therapies is often based on tumor biology, tumor location, surgical morbidity, and patient preference. Systemic therapy options have increased to include hormonal therapies, non-steroidal anti-inflammatory drugs and chemotherapy, as well as targeted therapies. Unfortunately, the rarity of this disease has resulted in a scarcity of randomized trials to Electronic supplementary material The online version of this article (doi:10.1007/s40487-016-0017-z) contains supplementary material, which is available to authorized users.
INTRODUCTION
Desmoid tumors present a difficult problem for both physician and patient. While many options for treatment are available, the natural history of this disease can be unpredictable resulting in a complex, multidisciplinary decision-making process with treatment algorithms that include combinations of radical surgery, systemic therapy and radiation, but may be as minimal as close observation. As a disease that has been referred to as a ''benign malignancy'' it may be challenging for patients to understand why such aggressive measures are needed for a disease that does not metastasize. Conversely, patients may be anxious about observing a tumor that has potential to grow and become locally invasive.
These tumors can occur nearly anywhere on the body, but this discussion will focus on the biology and treatment of abdominal wall desmoids and intra-abdominal desmoid tumors.
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
NATURAL HISTORY
Desmoid tumors are rare with an incidence of 0.03% of all neoplasms and 3% of soft tissue tumors [1] . The majority of desmoid tumors (also known as aggressive fibromatosis) occur sporadically, but can be associated with familial adenomatous polyposis syndrome (FAP).
FAP-associated desmoid tumors occur in 2-15% of all desmoid patients, and are typically located in the small bowel mesentery [2] [3] [4] [5] . Desmoids are seen more commonly in women than men with a 2:1 predilection for females [4, 6, 7] .
Young adult populations are most commonly affected and this disease is frequently seen in the 25-35 year old demographic [4, 6] . Histologically, desmoid tumors are a benign proliferation of myofibroblasts without a capsule that locally infiltrates surrounding tissues and may be multifocal. These characteristics result in a tumor that is difficult to control locally, but does not have the ability to metastasize [8-10]. Desmoids not only often occur on the abdominal wall or the mesentery of the small intestine, but also affect the shoulder girdle, chest wall and extremities. These tumors are often thought of as a chronic disease and require close observation regardless of treatment strategy as they have potential for mortality due to their locally aggressive behavior and ability to invade adjacent critical organs and structures [3] . (Table 1) . Large retrospective studies have shown higher The number of abdominal and abdominal wall cases is reported for each study. Recurrence rates as well as significance of margin status and radiation in preventing local recurrence are included. Patients were treated with surgery, radiation, and systemic therapy as either single agents or combination therapy n/a not applicable, R0 microscopically-negative margins, R1 surgically, but had a similar outcome as patients treated with R0 resection. Patients treated with observation did as well as patients with completely resected disease and better than patients with incomplete resection [39] . In an effort to understand how observation alone may affect additional therapies and outcomes for desmoid tumor, a multi-institutional study evaluated patients not treated with surgery or radiation and were stratified into an observation group or a medical therapy group. Eighty-three patients were treated with observation only and their progression was compared to patients treated systemically. The observation arm had a 49.9% 5-year progression-free survival (PFS) which was not different from the 58.6% PFS in the systemically treated group [40] . While the authors could not identify any prognostic factors that would predict tumor progression, they were able to avoid the morbidity of surgery and/or radiation. Of patients that did progress, While radiation has a role in treating desmoid tumors, the highly selected patients treated with radiation and the lack of randomized trials make the exact role for radiation in desmoids elusive.
RISK FACTORS AND GENETIC PREDISPOSITION
A large meta-analysis of patients from 22 studies treated with surgery, surgery plus radiation, or radiation alone suggested that all patients with desmoid tumors should be treated with radiation. Patients treated with radiation or radiation plus surgery had superior local control rates (78% and 75%, respectively) than patients treated with surgery alone (61%) [41] . While supporting the role for radiation as a viable treatment of desmoid tumors, the radiation doses in this study were highly variable and declaring that all disease should be treated with this modality may be overly aggressive and does not take into consideration the morbidity associated with radiation.
Complications related to radiation for desmoid fibromatosis are 17-23% [41] [42] [43] . Before radiation is given for abdominal wall and intra-abdominal desmoids the risk of radiation-induced enteritis as well as the risk of radiation-induced secondary malignancies should be considered. Radiation-induced malignancies are particularly relevant in a disease that often affects a younger cohort of patients [43] . Definitive radiation may be effective for local control in patients that would otherwise need radical and disfiguring surgery. Radiation as the primary mode of therapy for unresectable disease may offer a 70-80% chance of local control [42, 44, 45] This is likely related to a high risk of radiation-induced enteritis and the lack of a distinct target for grossly resected disease. Due to the lack of clearly defined indications for radiation it is critical to make these decisions in large volume multidisciplinary centers to properly select patients and avoid unnecessary exposure and morbidity from this treatment.
Systemic Therapy
Studies evaluating systemic therapy for desmoid fibromatosis frequently involve patients with mesenteric desmoid tumors due to the difficulty treating this situation with other therapies. In addition to high recurrence rates, there are significant side effects and morbidity that may arise from resection of mesenteric desmoids due to involvement of major blood vessels and potential need for significant bowel resection. Many systemic therapy represented. A response rate of over 85% was achieved (stable disease as well as responders) using anti-estrogen/NSAID therapy. Additionally they were able to taper therapy and had only one long-term recurrence in patients that had previously been resected [52] . Such a large cohort of patients with high response rates and durability is encouraging for non-surgical management of these tumors. This combination can be effective, but an objective response may take several months to stabilize disease and decrease associated symptoms [10, 48, 52] . These agents are often used as they are relatively inexpensive and have a low-risk side effect profile compared to other systemic therapies. Despite their relatively safe reputation it should be cautioned that anti-estrogens have a slightly increased risk of thromboembolic events and tamoxifen can cause ovarian cysts in pre-menopausal women.
Chemotherapy
Several studies have found chemotherapy to be the best systemic therapy for treating desmoid tumors with response rates as high as 79% [29, 48, 53] . There are a lack of randomized or controlled trials as most studies treat a small number of patients with heterogeneous treatment regimens. Drug combinations using anthracyclines appear to be the most effective treatment, but other combinations may additionally include methotrexate, vinblastine and cisplatin.
The anthracycline-based regimen has resulted in long progression-free survival and even complete responses. This has influenced some groups to support chemotherapy as first-line treatment for unresectable disease-particularly of the mesentery [29, 48, [53] [54] [55] [56] . Other studies have confirmed a high response rate and durable response for this regimen with progression-free survival of 74 months [53] . As might be expected, toxicity is higher with this regimen resulting in grade [3] [4] hematological toxicities in approximately 31-43% of patients [53, 56] .
Additionally, ''low-dose'' chemotherapy has also been described for systemic treatment of desmoids which typically includes methotrexate and vinblastine. This has been shown to be well tolerated and consistently results in stable or responding disease in 67-100% of patients treated [48, 56, 57] . Importantly, this regimen has also been associated with a prolonged response and 5-year progression-free survival as high as 67% [57] . Unfortunately this regimen has been associated with high toxicity rates resulting in patient intolerance and a 50% attrition rate.
Neurotoxicity is a common side effect of vinblastine that often results in patients not being able to tolerate this regimen. Another vinca alkaloid, vinorelbine, has been described as an effective agent against desmoids with less long-term toxicity than vinblastine and is also given with methotrexate [58, 59] . Weiss et al.
describe a 60% response rate and improvement of symptoms of 80% of patients treated with vinorelbine in a small series of patients with previously low rates of neurotoxicity [59] . This may likely be another useful regimen particularly in patients that do not tolerate vinblastine.
Targeted and Evolving Therapeutics
Other evolving options include targeted therapies using tyrosine kinase inhibitors (TKIs) and anti-angiogenic drugs. The TKI that have been used include imatinib and sunitinib.
A phase II trial using imatinib had modest results with 1-year progression-free survival of 66% and an objective response rate of only 6% [60] . Another phase II study using higher doses of imatinib (800 mg/day) revealed a 15.7%
partial response (PR) rate (C50% tumor shrinkage) in a heavily pre-treated group of patients. Interestingly, all patients that experienced a PR had intra-abdominal disease and duration of response was greater than 1.5 years for all patients [61] . Finally, Penel et al. treated 40 patients with imatinib (400 mg/day) in a phase II trial and experienced 67% progression-free survival.
Only 45.5% of these patients had abdominal wall or mesenteric disease, but two of these patients had a partial and durable response [62] .
Toxicity for all three of these trials was acceptable with very few grade 4 toxicities that were treated effectively with dose reduction. In addition to these phase II trials, other small retrospective reviews have revealed stable or partial response in 36-80% of patients with a median progression-free survival of nearly 27 months by Response Evaluation Criteria In Solid Tumors (RECIST) criteria [43] . Given the potential activity of imatinib in the treatment of desmoid fibromatosis, another TKI, sunitinib, has been evaluated for efficacy in The authors postulate that all of these events could be explained by the drugs anti-angiogenic affect with resultant tumor necrosis [63] . Additional TKI and anti-angiogenic drugs, sorafenib and pazopanib, have also been shown to have efficacy in treating desmoid tumors [64, 65] . In a small, retrospective review of 26 patients treated with sorafenib, 70% of patient reported improved symptoms, and at 6 months 95% of patients had either a partial response or stable disease. In the 13 patients with abdominal disease evaluated radiographically, nearly 73% of patients had radiographic response by RECIST criteria [64] . [66] . In an open label phase I dose escalation trial of a c-secretase inhibitor, five of seven patients with desmoid tumors that were treated showed objective and durable response [67] . This promising data has spawned a phase II trial evaluating a c-secretase inhibitor in adults with desmoid tumors [68] . Recently another target, hyaluronan (HA), a glycosaminoglycan in the stromal microenvironment involved with normal wound healing, has been identified and associated with desmoid tumorigenesis [69] .
This study identified overexpression of HA levels in desmoid tumor surgical specimens as well as immortalized cell lines. When HA synthesis was inhibited, they found decreased tumor proliferation rates and decreased HA levels suggesting a novel therapeutic target in treating desmoid fibromatosis. While new targets in this difficult disease are exciting, more translational studies will be required.
CONCLUSIONS
Due to the rarity and heterogeneity of this disease, it cannot be emphasized enough that desmoid fibromatosis should be managed within the context of a high-volume, multidisciplinary tumor board. Treatment recommendations regarding surgery, radiation, and systemic therapy are all evolving. This increases the complexity of the decision making for this disease and emphasizes the necessity of having surgical oncologists, radiation oncologists and medical oncologists involved in developing a treatment plan for each individual patient.
While more patients are being treated with observation for this disease, perhaps the most exciting and game-changing developments will come from genetic studies of these tumors. Once the pathophysiology of this disease is better understood, clinicians can better guide patients in treatment recommendations and risk stratification.
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